1. Introduction {#sec1-ijms-17-00164}
===============

Neuromelanin is a complex polymeric compound present in the human central nervous system which is synthesized mainly in dopaminergic neurons of the *substantia nigra* and in noradrenergic neurons of the *locus coeruleus* \[[@B1-ijms-17-00164],[@B2-ijms-17-00164]\]. The synthesis and accumulation of neuromelanin inside neurons arises during brain aging and there is evidence that neuromelanin is involved in the pathogenesis of neurodegenerative diseases such as Parkinson's disease \[[@B3-ijms-17-00164],[@B4-ijms-17-00164],[@B5-ijms-17-00164]\]. Notably, the *substantia nigra* and *locus coeruleus* are the areas in the brain with the highest concentration of neuromelanin pigment \[[@B6-ijms-17-00164]\].

The biosynthesis and structure of neuromelanin remains poorly understood, mainly because of difficulties in its isolation and the complexity of its structure \[[@B1-ijms-17-00164],[@B2-ijms-17-00164]\]. Nevertheless, our degradative approach suggested that the pigmented part of *substantia nigra* neuromelanin is derived from dopamine (DA) and cysteine in a molar ratio of 2:1 \[[@B7-ijms-17-00164],[@B8-ijms-17-00164]\]. In addition, it was recently suggested that various catecholic metabolites are incorporated into neuromelanin from the *substantia nigra* and *locus coeruleus*, including 3,4-dihydroxyphenylalanine (DOPA), 3,4-dihydroxyphenylethanol (DOPE, **1**), 3,4-dihydroxyphenylethylene glycol (DOPEG, **2**), 3,4-dihydroxyphenylacetic acid (DOPAC, **3**) and 3,4-dihydroxymandelic acid (DOMA, **4**), which are metabolites of dopamine (DA) and norepinephrine (NE) formed by the oxidative deamination by monoamine oxidase followed by reduction/oxidation ([Figure 1](#ijms-17-00164-f001){ref-type="fig"}) \[[@B9-ijms-17-00164],[@B10-ijms-17-00164],[@B11-ijms-17-00164]\].

Oxidation of those catecholamine metabolites leads to the production of *ortho*-quinones, although the nature of the oxidants remains controversial \[[@B12-ijms-17-00164]\]. Once formed, the *ortho*-quinones are trapped rapidly by cysteine (or other thiols) as long as it is present \[[@B13-ijms-17-00164]\]. The cysteine adducts are oxidized to give rise to pheomelanic pigments \[[@B9-ijms-17-00164],[@B10-ijms-17-00164]\]. After consumption of available cysteine in neurons, *ortho*-quinones derived from DA, NE and DOPA are cyclized to give aminochromes and eventually eumelanic pigments \[[@B9-ijms-17-00164],[@B10-ijms-17-00164],[@B13-ijms-17-00164]\]. Thus, the production of neuromelanin is considered as a detoxifying mechanism of otherwise toxic *ortho*-quinones \[[@B14-ijms-17-00164]\]. The fate of *ortho*-quinones derived from the catecholamine metabolites DOPE (**1**), DOPEG (**2**), DOPAC (**3**) and DOMA (**4**) are studied by kinetic and spectroscopic techniques and the results are presented in this paper.

![Possible participation of catecholic metabolites known to be present in various regions of the brain that may be incorporated into neuromelanin \[[@B7-ijms-17-00164],[@B8-ijms-17-00164]\]. In addition to dopamine (DA) and norepinephrine (NE) and the corresponding Cys-derivatives, these other metabolites are also thought to be incorporated into neuromelanin \[[@B9-ijms-17-00164],[@B10-ijms-17-00164]\]. *substantia nigra*, SN; *locus coeruleus*, LC; 3,4-dihydroxyphenylethanol, DOPE; 3,4-dihydroxyphenylethylene glycol, DOPEG; 3,4-dihydroxyphenylacetic acid, DOPAC; 3,4-dihydroxyphenylmandelic acid, DOMA; 3,4-dihydroxyphenylalanine, DOPA; cysteine, cys. The (O) represents the oxidants. Adapted from \[[@B10-ijms-17-00164]\] with minor modifications.](ijms-17-00164-g001){#ijms-17-00164-f001}

In this study, we compared the reactivities of those *ortho*-quinones regarding their half-lives and degradation products. *ortho*-Quinones are produced by oxidation with mushroom tyrosinase. The fates of *ortho*-quinones were examined by two methods \[[@B15-ijms-17-00164],[@B16-ijms-17-00164]\]: UV-visible spectrophotometry to detect *ortho*-quinones with an absorption maximum around 400 nm and HPLC to follow the degradation of *ortho*-quinones and the appearance of products after reduction to the corresponding catechols by NaBH~4~ or ascorbic acid. The results suggest that *ortho*-quinone products from catecholamine metabolites may not be incorporated into neuromelanin, but exert neurotoxicity as such because *ortho*-quinones are highly reactive compounds that lead to cytotoxicity through their binding to thiol enzymes and the production of reactive oxygen species \[[@B17-ijms-17-00164],[@B18-ijms-17-00164],[@B19-ijms-17-00164]\].

2. Results {#sec2-ijms-17-00164}
==========

2.1. Spectrophotometric Examinations {#sec2dot1-ijms-17-00164}
------------------------------------

The UV-visible spectrophotometric examinations were performed at a 100 µM concentration of the four catecholamine metabolites in 50 mM sodium phosphate buffer, pH 6.8 or 5.3, at 37 °C. The oxidation was initiated by adding 50 U/mL mushroom tyrosinase and was then periodically followed.

Spectral changes at pH 6.8 are shown in [Figure 2](#ijms-17-00164-f002){ref-type="fig"}. DOPE (**1**) and DOPEG (**2**) were oxidized to the corresponding *ortho*-quinones (400 nm) in 2 min and were then gradually degraded to ill-defined products after 60 min ([Figure 2](#ijms-17-00164-f002){ref-type="fig"}A,B). DOPAC (**3**) was converted to an *ortho*-quinone (400 nm) in 2 min but was rapidly degraded with a broader absorption ([Figure 2](#ijms-17-00164-f002){ref-type="fig"}C). DOMA (**4**) was oxidized to an *ortho*-quinone having an absorption maximum at 420 nm which may correspond to the *ortho*-quinone oxidation product of 3,4-dihydroxybenzaldehyde (DHBAld (**7**); [Figure 2](#ijms-17-00164-f002){ref-type="fig"}C,D; see below for the identification). Spectral changes at pH 5.3 are shown in [Figure S1](#app1-ijms-17-00164){ref-type="app"}. At pH 5.3, the *ortho*-quinones formed were much more stable than at pH 6.8 and showed more subtle spectral changes in 60 min.

![Time course of the degradation of *ortho*-quinone products from catecholamine metabolites, (**A**) DOPE (**1**); (**B**) DOPEG (**2**); (**C**) DOPAC (**3**); (**D**) DOMA (**4**). UV-visible spectral changes associated with the tyrosinase catalyzed oxidation of different catechols at pH 6.8. Each experiment was performed twice with similar results.](ijms-17-00164-g002){#ijms-17-00164-f002}

2.2. HPLC Examinations {#sec2dot2-ijms-17-00164}
----------------------

HPLC examinations were performed for the products after reduction of *ortho*-quinones with NaBH~4~ or ascorbic acid to the corresponding catechols ([Figure 3](#ijms-17-00164-f003){ref-type="fig"} and [Figure S2](#app1-ijms-17-00164){ref-type="app"}). The difference between reduction with NaBH~4~ and with ascorbic acid is that NaBH~4~ reduces not only the *ortho*-quinone moiety but also the carbonyl group to a hydroxyl group, whereas ascorbic acid is able to reduce only the former. HPLC conditions for the product analysis are summarized in [Table 1](#ijms-17-00164-t001){ref-type="table"}.

ijms-17-00164-t001_Table 1

###### 

Half-lives of *ortho*-quinone products from catecholamine metabolites (**1**--**4**) and HPLC conditions used to follow the oxidation.

  *Ortho*-Quinone Derived from        Half-Life (*t*~1/2~, min)   HPLC Conditions ^1^                       
  ----------------------------------- --------------------------- --------------------- --------- --------- --------------
  DOPE (**1**)                        14.6                        128                   15.2      114       80:20, 35 °C
  DOPEG (**2**)                       30.9                        187                   30.0      154       90:10, 35 °C
  DHBAlc (**6**) from DOPAC (**3**)   9.1                         46.8                  9.5       47.8      85:15, 50 °C
  DHBAld (**7**) from DOMA (**4**)    3.0 ^2^                     3.3 ^2^               3.0 ^2^   3.3 ^2^   85:15, 50 °C

^1^ The mobile phase of 0.4 M formic acid:methanol, *v*/*v* (%), and the column temperature; ^2^ These values were subject to experimental errors because of the rapid degradation of DHBAld (**7**)---quinone. DHBAlc, 3,4-dihydroxybenzylalcohol; DHBAld, 3,4-dihydroxybenzaldehyde.

HPLC following the oxidation of DOPE (**1**) at pH 6.8 showed a gradual degradation of DOPE (**1**)-quinone (analyzed as DOPE (**1**) after reduction with ascorbic acid (AA) or NaBH~4~) with production of a more hydrophilic compound with a shorter retention time compared to DOPE (**1**) ([Figure 3](#ijms-17-00164-f003){ref-type="fig"}A,B). The compound was found to have a UV absorption spectrum almost identical to DOPE (**1**) but different from the 3,4,6-trihydroxy chromophore of 6-hydroxydopamine ([Figure S3](#app1-ijms-17-00164){ref-type="app"}A). It was then identified as DOPEG (**2**) by co-injection on HPLC.

![HPLC following the degradation of *ortho*-quinone products from catecholamine metabolites at pH 6.8. (**A**,**B**) DOPE (**1**); (**C**,**D**) DOPEG (**2**); (**E**,**F**) DOPAC (**3**); (**G**,**H**) DOMA (**4**). For **A**, **C**, **E** and **G**, the oxidation was stopped by the addition of NaBH~4~; For **B**, **D**, **F** and **H**, the oxidation was stopped by the addition of ascorbic acid (AA). For the sake of clarity, the yields of DOPEG ketone (**5**) were multiplied by a factor of 10 in (**D**) and those of DHBAld (**7**) were by a factor of 5 in (**F**).](ijms-17-00164-g003){#ijms-17-00164-f003}

When analyzed after ascorbic acid reduction, the oxidation of DOPEG (**2**) gave a product with a longer retention time than DOPEG ([Figure 3](#ijms-17-00164-f003){ref-type="fig"}D). The compound was found to have a UV absorption spectrum almost identical to DHBAld (**7**) ([Figure S3](#app1-ijms-17-00164){ref-type="app"}B), suggesting it to have a carbonyl group adjacent to the 3,4-dihydroxyphenyl ring. To confirm its structure, the compound was prepared by NaIO~4~ oxidation of DOPEG (**2**) and isolated, although in a low yield (1%), by preparative HPLC. The compound was reduced by NaBH~4~ to afford DOPEG (**2**) ([Figure S4](#app1-ijms-17-00164){ref-type="app"}), suggesting that it is 2-oxo-DOPE (**5**). This identification was then confirmed by direct comparison with an authentic sample (see below). When analyzed after NaBH~4~ reduction, the 2-oxo-DOPE (**5**) actually formed was detected as DOPEG (**2**) ([Figure 3](#ijms-17-00164-f003){ref-type="fig"}C). Although the yield of 2-oxo-DOPE (**5**) is very low, it is a major product in the early phase of the degradation of DOPEG (**2**)-quinone. Its low yield can be ascribed to the slow conversion from DOPEG (**2**)-quinone and the high reactivity of its quinone form, similar to the unstable DHBAld (**7**)-quinone (see below). It should also be noted that *ortho*-quinones of DOPE (**1**) and DOPEG (**2**) did not undergo a cyclization reaction to form a five-membered ring. This is in contrast to the formation of a six-membered ring from the *ortho*-quinone of rhododendrol through the hydroxy group \[[@B13-ijms-17-00164]\].

When analyzed after ascorbic acid reduction, the oxidation of DOPAC (**3**) yielded 3,4-dihydroxybenzylalcohol (DHBAlc; **6**) as an initial and major product, which was gradually converted to DHBAld (**7**), although in low yield (**7**; [Figure 3](#ijms-17-00164-f003){ref-type="fig"}F). The identification of DHBAlc (**6**) and DHBAld (**7**) was confirmed by co-injection with authentic samples. The oxidation of DOMA (**4**) yielded DHBAld (**7**) as an initial and major product, which rapidly disappeared to give ill-defined polymeric product ([Figure 2](#ijms-17-00164-f002){ref-type="fig"}D and [Figure 3](#ijms-17-00164-f003){ref-type="fig"}H). The oxidation of DHBAld (**7**) itself afforded similar results on spectrophotometric and HPLC examinations (data not shown). The 3,4-dihydroxybenzoic acid, a possible product, was not detected. When analyzed after NaBH~4~ reduction, the DHBAld (**7**) actually formed was detected as DHBAlc (**6**) ([Figure 3](#ijms-17-00164-f003){ref-type="fig"}E,G).

In summary, 2-oxo-DOPE (**5**) was identified as the product of DOPEG (**2**)-quinone by ^1^H-NMR, ESI(+)/MS, and by co-injection on HPLC with the authentic sample provided by Manickam Sugumaran ([Figures S5 and S6](#app1-ijms-17-00164){ref-type="app"}). The catechol products from DOPE (**1**)-quinone, DOPAC (**3**)-quinone, and DOMA (**4**)-quinone were identified with the authentic samples.

HPLC following oxidation was also performed at pH 5.3 to examine the effect of pH on the fate of *ortho*-quinones as DOPEG (**2**), DHBAlc (**6**) and DHBAld (**7**) by comparison. As shown in [Figure S2](#app1-ijms-17-00164){ref-type="app"}, the *ortho*-quinones (analyzed as catechols after reduction) were much more stable at pH 5.3 than at pH 6.8, except for DHBAld (**7**) which degraded at similar rates at both pHs.

The half-lives of the *ortho*-quinones produced in this study are summarized in [Table 1](#ijms-17-00164-t001){ref-type="table"}. The reduction with NaBH~4~ or ascorbic acid gave similar results with differences within 10% of the averages. The stability of *ortho*-quinones was in the order of DOPEG (**2**)-quinone \> DOPE (**1**)-quinone \> DHBAlc (**6**)-quinone \> DHBAld (**7**)-quinone. These quinones were more reactive at pH 6.8 by a factor of 5--8 as compared to pH 5.3. An exception is that DHBAld (**7**)-quinone was as reactive at pH 5.3 as at pH 6.8.

3. Discussion {#sec3-ijms-17-00164}
=============

The catecholamines DA and NE are converted to alcoholic and acidic metabolites DOPE (**1**), DOPEG (**2**), DOPAC (**3**) and DOMA (**4**) in neurons ([Figure 1](#ijms-17-00164-f001){ref-type="fig"}). Our recent studies provided evidence for the incorporation of those catecholic metabolites into neuromelanins in the *substantia nigra* and the *locus coeruleus* in a pheomelanic structure \[[@B9-ijms-17-00164],[@B10-ijms-17-00164]\]. This result implies the involvement of *ortho*-quinone intermediates that are trapped by cysteine to form cysteinyl derivatives \[[@B9-ijms-17-00164],[@B10-ijms-17-00164],[@B13-ijms-17-00164]\]. In the present study, we used mushroom tyrosinase as an oxidant because it specifically and mildly oxidizes only catecholic substrates (and phenolic substrates) \[[@B15-ijms-17-00164],[@B16-ijms-17-00164],[@B20-ijms-17-00164]\]. Our results show that the quinone methide intermediates are produced from the *ortho*-quinones of **1**--**4** through deprotonation in DOPE (**1**) and DOPEG (**2**) or through decarboxylation in DOPAC (**3**) and DOMA (**4**). Those quinone methides undergo the addition of a water molecule to form alcohols or tautomerization to form carbonyl compounds. These reaction pathways are summarized in [Figure 4](#ijms-17-00164-f004){ref-type="fig"}.

![The metabolic fate of *ortho*-quinone products from catecholamine metabolites DOPE (**1**), DOPEG (**2**), DOPAC (**3**) and DOMA (**4**). The oxidation of DOPE (**1**) was stopped by the addition of NaBH~4~ or ascorbic acid (AA) to afford DOPEG (**2**). The oxidation of DOPEG (**2**) was stopped by the addition of AA to afford 2-oxo-DOPE (**5**). The oxidation of DOPAC (**3**) was stopped by the addition of AA to afford DHBAlc (**6**) and DHBAld (**7**). The oxidation of DOMA (**4**) was stopped by the addition of AA to afford DHBAld (**7**).](ijms-17-00164-g004){#ijms-17-00164-f004}

The metabolic fate of DOPE (**1**)-quinone was first reported by Sugumaran *et al.* \[[@B21-ijms-17-00164]\] using a preparation of cuticular enzyme(s) from *Sarcophaga bullota*. With that insect enzyme(s) they were able to show a rapid conversion of DOPE (**1**)-quinone to DOPEG (**2**) through the quinone methide intermediate. DOPEG (**2**) was then gradually converted to 2-oxo-DOPE (**5**). However, that series of reactions did not proceed beyond the DOPE (**1**)-quinone stage when DOPE (**1**) was oxidized by mushroom tyrosinase \[[@B21-ijms-17-00164]\]. The authors concluded that with the cuticular enzyme(s), quinone methide tautomerase acts on the *ortho*-quinone intermediate(s) to form quinone methide(s). The discrepancy between our results and theirs could be attributed to the fact that they followed the oxidation of DOPE (**1**) at a low concentration of tyrosinase while we followed the fate of DOPE (**1**)-quinone that was produced rapidly (\<2 min) by a high concentration of tyrosinase. Later studies on the fate of DOPE (**1**)-quinone by d'Ischia's group reported the production of a number of products, including dimers, but not DOPEG (**2**) \[[@B22-ijms-17-00164],[@B23-ijms-17-00164]\]. The discrepancy may arise from differences in the oxidant (tyrosinase *vs.* peroxidase plus hydrogen peroxide), the concentration (0.1 *vs*. 1 mM) and/or the pH (6.8 *vs*. 7.4). The concentration is exceptionally important because the quinone methide formation is a first-order reaction that is independent of the concentration, whereas the dimer production is a concentration-dependent, second-order reaction.

The metabolic fate of DOPEG (**2**)-quinone has not been extensively studied except for the above-mentioned report by Sugumaran *et al.* \[[@B21-ijms-17-00164]\]. In the present study, we identified the ketone metabolite of DOPEG (**2**), 2-oxo-DOPE (**5**), in the oxidation mixture when the oxidation was stopped by ascorbic acid (but not by NaBH~4~). The yield of this ketone was very low because of its high reactivity in the reaction mixture. In this connection, it should be mentioned that a similar, high reactivity of NE *ortho*-quinone yielded several side-chain breakdown products and a trimeric product, in addition to the cyclization products that eventually yield a melanic pigment \[[@B24-ijms-17-00164],[@B25-ijms-17-00164]\].

It has been reported that DOMA (**4**)-quinone, generated either enzymatically \[[@B26-ijms-17-00164],[@B27-ijms-17-00164]\] or electrochemically \[[@B28-ijms-17-00164]\], is converted to DHBAld (**7**) through a decarboxylative rearrangement giving a quinone methide intermediate ([Figure 4](#ijms-17-00164-f004){ref-type="fig"}). The reaction proceeds extremely quickly with a half-life of 0.4 s \[[@B28-ijms-17-00164]\]. DOPAC (**3**)-quinone also rapidly rearranges to give DHBAlc (**6**) through a quinone methide intermediate, and the product DHBAlc (**6**) is then gradually converted to DHBAld (**7**) through the same quinone methide as from DOMA (**4**)-quinone ([Figure 4](#ijms-17-00164-f004){ref-type="fig"}) \[[@B29-ijms-17-00164],[@B30-ijms-17-00164]\]. The present study has confirmed the results of those previous studies and has characterized the half-lives of DHBAlc (**6**)-quinone and DHBAld (**7**)-quinone, which indicates a high reactivity of the latter with a half-life of 3 min.

DOPAC (**3**)-quinone and DOMA (**4**)-quinone do not undergo a cyclization reaction giving a five-membered lactone ring in this study. This is in sharp contrast to the behavior of the *ortho*-quinone of dihydrocaffeic acid (3,4-dihydroxyphenylpropionic acid), which cyclizes to give a six-membered lactone ring with a half-life of 9.9 min \[[@B31-ijms-17-00164],[@B32-ijms-17-00164]\]. Sugumaran *et al.* \[[@B33-ijms-17-00164],[@B34-ijms-17-00164]\] previously studied the fate of DOPAC (**3**)-quinone enzymatically generated and identified 2,5,6-trihydroxybenzofuran, a cyclization product, in addition to DOMA (**4**) and DHBAld (**7**). In our study DHBAlc (**6**) was nearly quantitatively produced at 2 min ([Figure 3](#ijms-17-00164-f003){ref-type="fig"}E,F). The reason for this discrepancy between their results and ours is not clear at present. However, one major difference in the reaction conditions is that we used a very high ratio of tyrosinase to substrate to generate DOPAC (**3**)-quinone within 1--2 min while they used a much lower ratio to generate it (\>40 min).

The comparison of half-lives between pH 6.8 and 5.3 indicates that the quinone methide production from DOPE (**1**)-quinone, DOPEG (**2**)-quinone and DHBAlc (**6**)-quinone proceeds through the base-catalyzed mechanism as previously shown for 4-propyl-*o*-quinone by Bolton *et al.* \[[@B35-ijms-17-00164]\]. It appears that the formation of quinone methides is a rather common pathway of *ortho*-quinone metabolism, even in the absence of quinone methide tautomerase \[[@B27-ijms-17-00164],[@B36-ijms-17-00164]\]. For example, tyrosinase oxidation of 4-ethylphenol gives 1-(3,4-dihydroxyphenyl)ethanol as a major product \[[@B37-ijms-17-00164]\]. These *ortho*-quinones may exert strong toxicity to neurons through binding with thiol enzymes and the production of reactive oxygen species *in vivo* \[[@B17-ijms-17-00164],[@B18-ijms-17-00164],[@B19-ijms-17-00164]\]. In this regard, it should be worthwhile to point out that DHBAld (**7**)-quinone appears highly reactive as indicated by its short half-life of 3.0 min, the shortest among the *ortho*-quinones examined in this study ([Table 1](#ijms-17-00164-t001){ref-type="table"}).

In summary, the fate of *ortho*-quinones derived from the catecholamine metabolites DOPE (**1**), DOPEG (**2**), DOPAC (**3**) and DOMA (**4**) provided evidence for the facile production of quinone methides as transient intermediates, which yielded stable products upon aromatization.

4. Experimental Section {#sec4-ijms-17-00164}
=======================

4.1. Materials {#sec4dot1-ijms-17-00164}
--------------

Tyrosinase (from mushrooms, 1715 U/mg), 6-hydroxydopamine.HCl, DOPEG, DOPAC and DOMA were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 3,4-dihydroxybenzaldehyde (DHBAld), 3,4-dihydroxybenzoic acid, ascorbic acid, NaBH~4~, NaIO~4~, formic acid, and methanol were purchased from Wako Pure Chemical Industry (Osaka, Japan). DOPE was purchased from Tokyo Chemical Industry (Tokyo, Japan). A solution of DHBAlc was prepared by reducing DHBAld with NaBH~4~ as described in 4.3. The 2-oxo-2-(3,4-dihydroxyphenyl)ethanol (2-oxo-DOPE) was a kind gift from Manickam Sugumaran (University of Massachusetts Boston, Boston, MA, USA).

4.2. Instruments {#sec4dot2-ijms-17-00164}
----------------

UV-visible spectra were measured with a JASCO V-630 UV-VIS spectrophotometer connected with an HMC-711 water thermostatted cell holder (JASCO Co., Tokyo, Japan). The HPLC system used to follow the course of tyrosinase oxidation consisted of a JASCO PU-2080 Plus pump (JASCO Co., Tokyo, Japan), a Shiseido C18 column (Capcell Pak MG; 4.6 × 250 mm; 5 µm particle size, Shiseido, Tokyo, Japan) and a JASCO UV-visible detector at 280 nm (JASCO Co., Tokyo, Japan). The mobile phases were 0.4 M formic acid: methanol, 90:10, 85:15 or 80:20 (*v*/*v*) (see [Table 1](#ijms-17-00164-t001){ref-type="table"}). Analyses were performed at 35 or 50 °C (see [Table 1](#ijms-17-00164-t001){ref-type="table"}) and a flow rate of 0.7 mL/min. For preparative HPLC to isolate 2-oxo-DOPE, a Shiseido C18 column (Capcell Pak MG; 20 × 250 mm; 5 µm particle size) was used with a mobile phase of 0.4 M formic acid:methanol (80:20 (*v*/*v*)) at 35 °C at a flow rate of 7.0 mL/min. The ^1^H NMR (400 MHz) spectrum was obtained with a Bruker AVANCE 400 spectrophotometer (Billerica, MA, USA) which was calibrated by adding methanol (3.34 ppm). Mass spectra were obtained using an Esquire HCT Plus Ion Trap Mass Spectrometer (mode: ESI) (Bruker, Billerica, MA, USA).

4.3. Oxidation of Catecholamine Metabolites with Mushroom Tyrosinase and HPLC Following Oxidation {#sec4dot3-ijms-17-00164}
-------------------------------------------------------------------------------------------------

Stock solutions of metabolites were prepared in ethanol or water at a 10 mM concentration. Test solutions of metabolites were prepared by diluting them to 100 µM with 50 mM sodium phosphate buffer (pH 6.8 or 5.3) when needed. A solution (2 mL) of 100 µM metabolite was oxidized by adding 20 µL (100 U) mushroom tyrosinase at 37 °C. The same amount of tyrosinase was also added to the reference cuvette. The oxidation was followed periodically up to 60 min with the UV-visible spectrophotometer. For HPLC following oxidation, a solution (1 mL) of 100 µM metabolite was oxidized by adding 20 µL (100 U) mushroom tyrosinase at 37 °C. The amount of tyrosinase was doubled in the HPLC analyses compared to the spectrophotometric analyses, so that oxidation of *ortho*-quinones completes faster, because we observed that oxidation of DOMA took several minutes to complete in the spectrophotometric analysis ([Figure 2](#ijms-17-00164-f002){ref-type="fig"}D). Aliquots of the reaction mixtures were periodically (2, 5, 10, 15, 30 and 60 min) withdrawn and subjected to analysis after reduction. For reductive termination of the reaction, 100 µL aliquots were mixed with 20 µL 10% NaBH~4~ or 5 mM ascorbic acid in water followed by the addition of 100 µL 0.8 M perchloric acid.

The half-lives (*t*~1/2~) of the *ortho*-quinones produced were calculated using the equation ln(c~0~/c) = *kt* and *kt*~1/2~ = 0.693.

4.4. Preparation of 2-Oxo-DOPE (**5**) {#sec4dot4-ijms-17-00164}
--------------------------------------

A solution of DOPEG (**2**) (17.0 mg, 0.1 mmol) in 100 mL 50 mM sodium phosphate buffer (pH 6.8) was gently shaken at 37 °C, to which NaIO~4~ (21.4 mg, 0.1 mmol) in 1 mL water was slowly added in 2 min. After 30 min, the mixture was poured into a solution of ascorbic acid (352 mg, 2 mmol) in 10 mL water. The mixture was extracted three times with ethyl acetate (100 mL each) and the combined ethyl acetate extract was dried over anhydrous sodium sulfate. The extract was evaporated under reduced pressure to give an oily residue, which was subjected to preparative HPLC to afford, after lyophilization, *ca.* 0.2 mg (HPLC purity, 98%; NMR purity, 91%) of 2-oxo-DOPE (**5**). Tyrosinase oxidation gave a lower yield of **5**. ^1^H NMR (400 MHz, CD~3~OD) δ 4.78 (2H, s, CH~2~), 6.81 (1H, d, *J* = 8.8 Hz, H-2'), 7.36 (1H, dd, *J* = 8.8, 2.0 Hz, H-6'), 7.37 (1H, d, *J* = 2.0 Hz, H-5') ([Figure S5](#app1-ijms-17-00164){ref-type="app"}). ESI(+)/MS: *m/z* 191.03 (\[M + Na\])^+^, 33%) 169.05 (\[M + H\]^+^, 100%) ([Figure S6](#app1-ijms-17-00164){ref-type="app"}).

5. Conclusions {#sec5-ijms-17-00164}
==============

This study confirmed the fact that *ortho*-quinones from catechols **1**--**4** are converted to quinone methide tautomers as common intermediates, through proton rearrangement or decarboxylation. The unstable quinone methides afford stable alcoholic or carbonyl products ([Figure 4](#ijms-17-00164-f004){ref-type="fig"}). In *substantia nigra* and *locus coeruleus* neurons, the production of neuromelanin appears to detoxify otherwise toxic DA-quinone and NE-quinone \[[@B12-ijms-17-00164],[@B14-ijms-17-00164]\]. Since it is likely that the formation of those *ortho*-quinones does not lead to incorporation into neuromelanin, the *ortho*-quinone of catecholamine metabolites, once formed, may exert cytotoxicity to neurons.
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